Sangamo Therapeutics Inc - Company & Market Research Reports

Sangamo BioSciences is a biotechnology company that develops industry leading technologies in gene therapy, genome editing, cell therapy and gene regulation. The company is focused on pioneering genetic cures for monogenic and infectious diseases by deploying its AAV-based gene therapy platform, and therapeutic genome editing and gene regulation platforms based on its novel zinc finger DNA-binding protein technology. Sangamo is headquartered in Richmond, California.

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018 - Product Thumbnail Image

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1005 Pages
From
HIV / AIDS - Pipeline Review, H1 2016 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2016

  • Drug Pipelines
  • 886 Pages
From
Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Product Thumbnail Image

Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • Report
  • 116 Pages
From
HIV / AIDS - Pipeline Review, H2 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H2 2015

  • Drug Pipelines
  • 916 Pages
From
Thalassemia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Thalassemia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 98 Pages
From
HIV / AIDS - Pipeline Review, H1 2015 - Product Thumbnail Image

HIV / AIDS - Pipeline Review, H1 2015

  • Drug Pipelines
  • 871 Pages
From
Sickle Cell Disease Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Sickle Cell Disease Drug Development Pipeline Review, 2017

  • Report
  • 77 Pages
From
Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 85 Pages
From
2018 Sickle Cell Disease Or Sickle Cell Anemia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Sickle Cell Disease Or Sickle Cell Anemia Market - Product Thumbnail Image

2018 Sickle Cell Disease Or Sickle Cell Anemia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Sickle Cell Disease Or Sickle Cell Anemia Market

  • Report
  • 70 Pages
From
TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist -Pipeline Insight, 2018 - Product Thumbnail Image

TRK1-Transforming Tyrosine Kinase (Trk-A or High Affinity Nerve Growth Factor Receptor) Antagonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
T-Cell Immunotherapy Market (2nd Edition), 2017-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • Report
  • 654 Pages
From
T-Cell Immunotherapy Market (3rd Edition), 2018-2030 - Product Thumbnail Image

T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • Report
  • 850 Pages
From
Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024 - Product Thumbnail Image

Global Sickle Cell Anemia Drug Market, Price, Dosage & Clinical Pipeline Outlook 2024

  • Report
  • 170 Pages
From
World Hemoglobinopathies Market - Opportunities and Forecasts, 2017 - 2023 - Product Thumbnail Image

World Hemoglobinopathies Market - Opportunities and Forecasts, 2017 - 2023

  • Report
From
Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018 - Product Thumbnail Image

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 68 Pages
From
CAR-T Therapies Market, 2018-2030 - Product Thumbnail Image

CAR-T Therapies Market, 2018-2030

  • Report
  • 548 Pages
From
Global Factor VIII Deficiency Treatment Market 2017-2021 - Product Thumbnail Image

Global Factor VIII Deficiency Treatment Market 2017-2021

  • Report
  • 70 Pages
From
Global Hemophilia Drugs Market 2016-2020 - Product Thumbnail Image

Global Hemophilia Drugs Market 2016-2020

  • Report
  • 84 Pages
From
Market Spotlight: Amyotrophic Lateral Sclerosis (ALS) - Product Thumbnail Image

Market Spotlight: Amyotrophic Lateral Sclerosis (ALS)

  • Report
  • 36 Pages
From
Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023 - Product Thumbnail Image

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023

  • Report
  • 89 Pages
From
Loading Indicator
adroll